106 related articles for article (PubMed ID: 24585409)
1. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
Stevens VL; Jacobs EJ; Sun J; Gapstur SM
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):890-2. PubMed ID: 24585409
[TBL] [Abstract][Full Text] [Related]
2. Obesity, adipokines, and prostate cancer in a prospective population-based study.
Baillargeon J; Platz EA; Rose DP; Pollock BH; Ankerst DP; Haffner S; Higgins B; Lokshin A; Troyer D; Hernandez J; Lynch S; Leach RJ; Thompson IM
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1331-5. PubMed ID: 16835332
[TBL] [Abstract][Full Text] [Related]
3. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
Jacobs EJ; Stevens VL; Newton CC; Gapstur SM
Cancer Causes Control; 2012 Aug; 23(8):1289-96. PubMed ID: 22692409
[TBL] [Abstract][Full Text] [Related]
4. Height, predictors of C-peptide and cancer risk in men.
Giovannucci E; Rimm EB; Liu Y; Willett WC
Int J Epidemiol; 2004 Feb; 33(1):217-25. PubMed ID: 15075172
[TBL] [Abstract][Full Text] [Related]
5. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.
Gann PH; Ma J; Giovannucci E; Willett W; Sacks FM; Hennekens CH; Stampfer MJ
Cancer Res; 1999 Mar; 59(6):1225-30. PubMed ID: 10096552
[TBL] [Abstract][Full Text] [Related]
6. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
7. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
8. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
9. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
Rodriguez C; Freedland SJ; Deka A; Jacobs EJ; McCullough ML; Patel AV; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):63-9. PubMed ID: 17179486
[TBL] [Abstract][Full Text] [Related]
10. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
Li H; Kantoff PW; Ma J; Stampfer MJ; George DJ
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1557-61. PubMed ID: 15941972
[TBL] [Abstract][Full Text] [Related]
11. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
Gann PH; Ma J; Hennekens CH; Hollis BW; Haddad JG; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):121-6. PubMed ID: 8850273
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer and adiponectin.
Goktas S; Yilmaz MI; Caglar K; Sonmez A; Kilic S; Bedir S
Urology; 2005 Jun; 65(6):1168-72. PubMed ID: 15922427
[TBL] [Abstract][Full Text] [Related]
13. Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study.
Lai GY; Helzlsouer KJ; Clipp SL; Rifai N; Platz EA
Cancer Prev Res (Phila); 2010 Oct; 3(10):1334-41. PubMed ID: 20858760
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study.
Michikawa T; Inoue M; Sawada N; Sasazuki S; Tanaka Y; Iwasaki M; Shimazu T; Yamaji T; Mizokami M; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2250-7. PubMed ID: 24045928
[TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
16. Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?
Nogueira LM; Newton CC; Pollak M; Silverman DT; Albanes D; Männistö S; Weinstein SJ; Jacobs EJ; Stolzenberg-Solomon RZ
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):914-922. PubMed ID: 28096201
[No Abstract] [Full Text] [Related]
17. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
18. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study.
Wei EK; Giovannucci E; Fuchs CS; Willett WC; Mantzoros CS
J Natl Cancer Inst; 2005 Nov; 97(22):1688-94. PubMed ID: 16288122
[TBL] [Abstract][Full Text] [Related]
19. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
Eliassen AH; Tworoger SS; Mantzoros CS; Pollak MN; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):161-4. PubMed ID: 17220346
[TBL] [Abstract][Full Text] [Related]
20. Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer.
Di Sebastiano KM; Pinthus JH; Duivenvoorden WC; Patterson L; Dubin JA; Mourtzakis M
Prostate; 2017 Feb; 77(2):211-221. PubMed ID: 27699825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
